In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece

ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa

(2019) José-Manuel Ortiz de la Rosa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

(2019) Ilias Karaiskos et al.   Frontiers in Public Health

Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

(2019) Juan P. Horcajada et al.   CLINICAL MICROBIOLOGY REVIEWS

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

(2018) Veronica Rico Caballero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm

(2018) Raúl Recio et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The Versatile Mutational Resistome of Pseudomonas aeruginosa

(2018) Carla López-Causapé et al.   Frontiers in Microbiology

Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

(2018) Lynn Nguyen et al.   Current Infectious Disease Reports

Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam

(2018) Fernando Sanz-García et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art

(2017) Alberto Enrico Maraolo et al.   Expert Review of Anti-Infective Therapy

Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis

(2017) Carla López-Causapé et al.   Future Microbiology

Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods

(2017) Frieder Schaumburg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa

(2017) Marguerite L Monogue et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents

(2017) Cédric Jacqueline et al.   Journal of Global Antimicrobial Resistance

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations

(2016) Rachel L. Soon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation

(2016) Marguerite L. Monogue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful control of an outbreak of GES-5 extended-spectrum β-lactamase-producing Pseudomonas aeruginosa in a long-term care facility in Japan

(2016) A. Kanayama et al.   JOURNAL OF HOSPITAL INFECTION

Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania

(2015) G. Mikucionyte et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen

(2014) Etienne de Montmollin et al.   INTENSIVE CARE MEDICINE

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)

(2014) Helio S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program

(2013) Brian J. Morrow et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

How antibiotics kill bacteria: from targets to networks

(2010) Michael A. Kohanski et al.   NATURE REVIEWS MICROBIOLOGY